TransMedics Group, Inc. Aktie News

ANDOVER, Mass., Jan. 12, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, as well as the acquisition of the adjacent land parcel to create an integrated TransMedics campus environment.

ANDOVER, Mass., Dec. 30, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 44th Annual J.P.

These healthcare growth stocks are profitable and revenue is growing at a double-digit pace. Intuitive Surgical is the top global player in the field of robotic surgery.

ANDOVER, Mass. , Dec. 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 22, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 6,333 shares of its common stock and an ...

TransMedics is reaffirmed as a buy, with significant upside potential based on improved margins and slower share dilution. I estimate 2028 revenue at $1.35 billion, driven by achieving 10k transplants at a $105,000 average price, plus $300 million in additional revenue. Net income margin is now forecast at 17.5% for 2028, with long-term potential to exceed 20%, as seen in peer medical device co...

Investment strategist Shay Boloor has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit from powerful long-term trends heading into 2026.

TransMedics Group's revolutionary organ care system is driving its strong results. Abivax is a David among Goliaths, and its growth story might just be getting started.

Director Edward Basile executed an exercise of 4,142 options with immediate sale of all resulting shares in TransMedics Group (TMDX +0.07%) on October 29, 2025, as disclosed in the SEC Form 4 filing.